Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Immunology Miniatures

An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer

Encouse B. Golden, Sandra Demaria, Peter B. Schiff, Abraham Chachoua and Silvia C. Formenti
Encouse B. Golden
Authors' Affiliations: Departments of Radiation Oncology, Pathology, and Medicine, New York University School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Demaria
Authors' Affiliations: Departments of Radiation Oncology, Pathology, and Medicine, New York University School of Medicine, New York, New YorkAuthors' Affiliations: Departments of Radiation Oncology, Pathology, and Medicine, New York University School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter B. Schiff
Authors' Affiliations: Departments of Radiation Oncology, Pathology, and Medicine, New York University School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abraham Chachoua
Authors' Affiliations: Departments of Radiation Oncology, Pathology, and Medicine, New York University School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia C. Formenti
Authors' Affiliations: Departments of Radiation Oncology, Pathology, and Medicine, New York University School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6066.CIR-13-0115 Published December 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Registration of PET/CT and CT/simulation to target intrahepatic lesion. The PET/CT from August 2012 (left) was imported into the Eclipse planning software (Varian Medical Systems, Inc.) and registered to the CT/simulation (right) that was acquired before treatment. Selected axial (top), coronal (middle), and sagittal (bottom) images are displayed. The most hypermetabolic liver lesion was selected as the gross tumor volume (white arrows, left). The treatment plan was designed with 6-MV photons by means of a coplanar five-field intensity-modulated technique to encompass the gross tumor volume with a 1-cm margin (right). The treatment was prescribed to the 100% isodose line to a total dose of 30 Gy distributed over five fractions. The isodose lines represent total doses of 30 Gy (yellow), 15 Gy (orange), and 9 Gy (light blue; right).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Ipilimumab and local radiotherapy result in an abscopal response. PET imaging and select fused PET/CT axial images from August 2012 (left) and January 2013 (right) are displayed. The axial images in the second row reveal the hypermetabolic liver lesion that was targeted and responded to radiotherapy (white arrows, second row). An abscopal response was seen in a left lower lobe lung lesion (white arrows, third row) and a left sacral lesion (white arrows, bottom row). A mixed response was seen in the hilar/mediastinal lymph nodes (striped arrows, third row).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Treatment timeline and the absolute peripheral blood cell counts. A detailed clinical timeline is displayed (A, top). A PET/CT on June 8, 2012, showed disease progression, prompting a change in the patient's chemotherapy regimen. On June 15, 2012, the patient was started on a chemotherapy regimen containing gemcitabine and vinorelbine. The green marker indicates the treatment timeline for gemcitabine and vinorelbine (A, top). A repeat PET/CT on August 6, 2012, showed continued disease progression. From August 22, 2012, to August 31, 2012, the patient was treated with concurrent radiotherapy (RT) and ipilimumab. Afterward, he received three additional cycles of ipilimumab alone. The blue marker indicates the treatment timeline for radiotherapy and ipilimumab [A (top) and B], and data plotted to the right of the vertical dashed line in each graph represents postinitiation of radiotherapy and ipilimumab treatment [A (bottom three graphs) and B]. The final dose of ipilimumab was given on October 26, 2012. Imaging on November 8, 2012 (CT of the chest, abdomen, and pelvis) and January 17, 2013 (PET/CT), showed significant treatment responses. During the course of treatment, the patient had serial blood draws. The results of the peripheral absolute blood cell counts [white blood cells (WBC), absolute leukocyte count (ALC), and absolute eosinophil count (AEC)] are displayed as number of cells (×103) per μL of whole blood (A, bottom three graphs), in accordance with the aforementioned treatment timeline (A, top). A dramatic drop in carcinoembryonic antigen levels (a nonspecific tumor marker) was observed after treatment with radiotherapy and ipilimumab (B). The marker peaked at 119.6 ng/mL (normal levels 0–5 ng/mL) on September 7, 2012, showing a dramatic drop to 5.8 ng/mL on October 26, 2012, and thereafter was maintained at normal levels.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Enhanced tumor-infiltrating lymphocytes in an abscopal lesion. A treatment-naïve left supraclavicular nodal metastasis was excised in 2010 and an adjacent nonirradiated nodal metastasis was excised in 2013 (following treatment with ipilimumab and local radiotherapy). The immunologic characteristics of the two specimens were compared (A). A hematoxylin and eosin (H&E) stain showed lymphocytic infiltration largely confined to perivascular areas in the 2010 biopsy specimen (A, top left–black arrow), whereas lymphocyte-infiltrated tumor cells nests in the 2013 biopsy specimen (A, top right–white arrow). Rare CD8+ cells were present in the 2010 specimen (A, middle left). However, a marked increase in CD8+ and TIA+ (a marker for cytotoxic granules) cells was present in the 2013 specimen (A, middle right). The inset shows TIA-1+ cells directly interacting with tumor cells (A, bottom right). Cells were counted in 10 randomly selected high-power fields (HPF; B). CD8+ cells were significantly increased (P < 0.0001) in the biopsy from 2013. FoxP3+ cells also increased (P < 0.05), but the ratio of CD8+/FoxP3+ cells was higher in the 2013 specimen.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    PET image 1 year after treatment with concurrent radiotherapy and ipilimumab. A PET/CT was completed in September 2013. The PET image is displayed and reveals no evidence of disease.

PreviousNext
Back to top
Cancer Immunology Research: 1 (6)
December 2013
Volume 1, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
Citation Tools
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
Encouse B. Golden, Sandra Demaria, Peter B. Schiff, Abraham Chachoua and Silvia C. Formenti
Cancer Immunol Res December 1 2013 (1) (6) 365-372; DOI: 10.1158/2326-6066.CIR-13-0115

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
Encouse B. Golden, Sandra Demaria, Peter B. Schiff, Abraham Chachoua and Silvia C. Formenti
Cancer Immunol Res December 1 2013 (1) (6) 365-372; DOI: 10.1158/2326-6066.CIR-13-0115
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Case Presentation
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Anti–PD-1 Pneumonitis and Persistent Imaging Abnormalities
  • The First Pipeline for Validating Personalized Neoantigens
  • Immunopathologic Stratification of Colorectal Cancer
Show more Cancer Immunology Miniatures
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement